Efficacy and safety of oral factor Xa inhibitors versus vitamin-K antagonists in the early phase after acute ischemic stroke or TIA in the real-world setting: The PRODAST study.

3 – 6 In addition, two randomized trials have addressed this topic: The TIMING trial randomized 888 patients with ischemic stroke to early initiation of anticoagulation with non-vitamin K dependent oral anticoagulants (NOACs) within 4 days compared to a start at 5–10 days and found a strong trend in favor of an early anticoagulation. 7 The ELAN trial randomized 2,013 participants with ischemic stroke and AF and also found numerical superiority of early anticoagulation over later anticoagulation. 8 Beyond the results of randomized trials, however, data from prospective registry studies are also necessary and important in order to reflect everyday clinical practice and to include patients who were not included in randomized trials.

also in 5,725 other papers